Why the study?
Does imatinib induce thyroid dysfunction in newly diagnosed CML patients?
Observational (n=26)
No
Does imatinib induce thyroid dysfunction in newly diagnosed CML patients?
Imatinib therapy for 6 months in CML patients caused a statistically significant but clinically mild increase in TSH, with the vast majority of patients remaining euthyroid.
Answers are grounded in this paper and cite their sources.
Mild TSH rise with imatinib warrants no routine intervention in CML; leaves open long-term thyroid effects.
Background: Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder. It is associated with acquired genetic changes in the hematopoietic stem cells in the form of BCR-ABL fusion gene also known as Philadelphia chromosome. Materials and methods: We prospectively studied thyroid function at baseline and at 6 months of imatinib treatment in 26 newly diagnosed BCR-ABL positive CML patients. Result: . 3.724 ± 1.726 mIU/L, p < 0.05) after 6 months of treatment, 88.4% of the patients remained euthyroid. Only 2 patients had subclinical hypothyroidism, 1 had hypothyroidism after 6 months of tyrosine kinase inhibitors (TKI) therapy. Conclusion: Imatinib did not have any significant effect on thyroid function in CML patients in this study.
No takes yet. Share an insight, caveat, or question.
Malhotra et al. (2023) conducted an observational in Chronic myelogenous leukemia (n=26). Tyrosine kinase inhibitors (Imatinib) vs. Baseline (pre-treatment) was evaluated on Change in thyroid-stimulating hormone (TSH) levels (Mean difference 0.524, p=0.009).
Synapse has enriched 10 related papers. Consider them for comparative context: